

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2020 P 1346-1
Program	Notification- California
Medication	HIV Medications with Pre-exposure Prophylaxis (PrEP) Use Zero Dollar Cost Share- California - Descovy and generic tenofovir fumarate 300mg
P&T Approval Date	12/2020
Effective Date	1/1/2021; Oxford only: N/A

1. Background:

California regulations require the use of HIV medications for Pre-Exposure Prophylaxis to be covered at zero dollar cost share upon request.

2. Coverage Criteria:

A. Pre-Exposure Prophylaxis (PrEP):

1. Preventive care coverage for pre-exposure prophylaxis (PrEP) is being requested for either Descovy or tenofovir 300 mg

Authorization will be issued for zero copay with deductible bypass for 12 months.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.

4. References:

1. U.S. Preventive Services Task Force Final Recommendation Statement *Prevention of Human Immunodeficiency Virus (HIV) Infection: Pre-exposure Prophylaxis*
<https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis#consider> Accessed August 7, 2020
2. US Public Health Service Pre-exposure Prophylaxis For The Prevention Of HIV Infection In The United States – 2017 Update – A Clinical Practice Guideline
<https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf> Accessed August 7, 2020

Program	HIV Medications with Pre-exposure Prophylaxis (PrEP) Use-California
Change Control	
Date	Change
12/2020	New program.